|
Remdesivir to Treat Novel Coronavirus (2019-nCoV)
|
|
| Author:
|
R. ANANDAN, S. THIRUMAL, B.S. DEEPAK
|
| Abstract:
|
Novel Coronavirus (2019-nCoV) or Human Coronavirus (HCoV) could be a new coronavirus that belongs to Betacoronaviruses type Human Coronaviruses, just like the Middle-East Respiratory Syndrome (MERS) coro-navirus and Severe Acute Respiratory Syndrome (SARS) coronavirus. Wuhan, the capital city of Hubei prov-ince, China recorded the primary case of this virus in December 2019. Until 27 March 2020, 10:00 CET, near 23,335 deaths were reported out of 509,164 confirmed cases recorded across the world. By the tip of January 2020, China confirmed that the COVID-19 transmitted from human to human. This study aims to check a completely unique medicament called “Remdesivir” (development code G S-5734) against the crystal structure of 2019-nCoV Main Protease. This study presents an ideal model for Remdesivir (anti-polymerase drug) to be tested in silico against 2019-nCoV Main Protease.
|
| Keyword:
|
Remdesivir, COVID-19, 2019-nC0V, Human Coronavirus.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.12.02.252
|
| Download:
|
Request For Article
|
|
|